key: cord-0984005-091hhtji
authors: Lee, Grace C.; Restrepo, Marcos I.; Harper, Nathan; Manoharan, Muthu Saravanan; Smith, Alisha M.; Meunier, Justin A.; Sanchez-Reilly, Sandra; Ehsan, Aamir; Branum, Anne P.; Winter, Caitlyn; Winter, Lauryn; Jimenez, Fabio; Pandranki, Lavanya; Carrillo, Andrew; Perez, Graciela L.; Anzueto, Antonio; Trinh, Hanh; Lee, Monica; Hecht, Joan M.; Martinez, Celida; Sehgal, Raj T.; Cadena, Jose; Walter, Elizabeth A.; Oakman, Kimberly; Benavides, Raymond; Pugh, Jacqueline A.; Letendre, Scott; Steri, Maristella; Orrù, Valeria; Fiorillo, Edoardo; Cucca, Francesco; Moreira, Alvaro G.; Zhang, Nu; Leadbetter, Elizabeth; Agan, Brian K.; Richman, Douglas D.; He, Weijing; Clark, Robert A.; Okulicz, Jason F.; Ahuja, Sunil K.
title: Immunologic resilience and COVID-19 survival advantage
date: 2021-09-08
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2021.08.021
sha: c0fa558241b1f6a8064d243c9e5c3a59134ba8e2
doc_id: 984005
cord_uid: 091hhtji

Background The risk of severe COVID-19 varies significantly among persons of similar age and is higher in males. Age-independent, sex-biased differences in susceptibility to severe COVID-19 may be ascribable to deficits in a sexually dimorphic protective attribute that we termed immunologic resilience (IR). Objective To examine whether deficits in IR that antedate or are induced by SARS-CoV-2 infection independently predict COVID-19 mortality. Methods IR levels were quantified with two novel metrics: immune health grades (IHG-I [best] to IHG-IV) to gauge CD8+ and CD4+ T-cell count equilibrium, and blood gene expression signatures. IR metrics were examined in a prospective COVID-19 cohort (n=522); primary outcome was 30-day mortality. Associations of IR metrics with outcomes in non-COVID-19 cohorts (n=13,461) provided the framework for linking pre-COVID-19 IR status to IR during COVID-19, as well as to clinical outcomes. Results IHG-I, tracking high-grade equilibrium between CD8+ and CD4+ T-cell counts, was the most common grade (73%) among healthy adults, particularly in females. SARS-CoV-2 infection associated with underrepresentation of IHG-I (21%) vs. overrepresentation (77%) of IHG-II or IHG-IV, especially in males vs. females (P<0.01). Presentation with IHG-I associated with 88% lower mortality, after controlling for age and sex; reduced risk of hospitalization and respiratory failure; lower plasma IL-6 levels; rapid clearance of nasopharyngeal SARS-CoV-2 burden; and gene expression signatures correlating with survival that signify immunocompetence and controlled inflammation. In non-COVID-19 cohorts, IR-preserving metrics associated with resistance to progressive influenza or HIV infection, as well as lower 9-year mortality in the Framingham Heart Study, especially in females. Conclusion Preservation of immunocompetence with controlled inflammation during antigenic challenges is a hallmark of IR and associates with longevity and AIDS resistance. Independent of age, a male-biased proclivity to degrade IR before and/or during SARS-CoV-2 infection predisposes to severe COVID-19. Clinical implications Biomarkers tracking immunologic resilience may have broad prognostic utility, as they associated with longevity, as well as resistance to a progressive disease course during SARS-CoV-2, influenza, or HIV infection.

Despite significant progress in the identification of host factors that influence COVID-19 166 outcomes 1-7 , the reasons why persons of similar ages vary in their susceptibility to 167 developing progressive COVID-19, characterized by hospitalization, respiratory failure, 168 and death, are unclear. We sought to identify persons with this susceptibility through the 169 articulation of a parsimonious basis for three conundrums. First, while the risk of 170 progressive COVID-19 increases with age, some older persons resist progression, 171 manifesting asymptomatic or mild (i.e., nonprogressive) COVID-19 1, 2 , whereas, some 172 younger persons manifest progressive 4 . Second, females appear to resist 173 progressive COVID-19 more effectively than males 5, 6, 8, 9 . This resistance aligns with 174 evidence that females often manifest features of superior immunocompetence 175 (resistance to some infections, longevity 10-17 ). Third, clearance rates of nasopharyngeal 176 SARS-CoV-2 vary, with delays contributing to progressive 19 . 177

We reasoned that a parsimonious basis for these conundrums is that, among persons of 179 similar ages, progressive COVID-19 is ascribable to a deficit in a sexually dimorphic, 180 immunity-optimizing attribute that antedates infection or is induced by SARS-CoV-2 181 infection. We termed this attribute as immunologic resilience (IR), defined as the capacity 182 to preserve or restore immunocompetence and control inflammation in the face of 183 antigenic challenges experienced throughout life. Thus, we posited that maintenance of 184 a state of higher immunocompetence (IC) and lower inflammation (IF; IC high -IF low ) 185 constitutively and/or during antigenic exposures is the hallmark of IR. 186 187 J o u r n a l P r e -p r o o f

In this context, we hypothesized that individuals of similar ages may differ in their capacity 188 to preserve IR before and during COVID-19, defining three major IR-dependent COVID-189 19 phenotypes (Table 1) . In SARS-CoV-2-negative persons, a deficit in IR is 190 characterized by an immunosuppressive, pro-inflammatory state (IC low -IF high ) that is more 191 common in males and predisposes to a shorter lifespan, as well as a progressive disease 192 course during viral infections, such as influenza and HIV. If such persons acquire CoV-2 infection, the pre-existing deficit in IR may increase susceptibility to development 194 of progressive COVID-19 as well as amplify SARS-CoV-2-induced deficits in IR 195 (phenotype 3; Table 1 ). In contrast, resistance to developing deficits in IR before and 196 during SARS-CoV-2 infection associates with nonprogressive COVID-19 (phenotype 1; 197 Table 1 ). Thus, persons with the IR-dependent COVID-19 phenotype 3 may manifest two 198 distinct IC low -IF high states: one antedating infection and one induced by To test our hypothesis, we developed novel laboratory (lymphocyte level-based) and 201 transcriptomic (gene expression-based) metrics of IR. We juxtaposed the distributions 202 and associations of IR metrics in a prospective COVID-19 cohort with those in cohorts of 203 SARS-CoV-2-negative persons. This juxtaposition provided empiric evidence in support 204 of three IR-dependent COVID-19 phenotypes (Table 1) . Additionally, we evaluated the 205 utility of IR metrics in the early prediction of all-cause 30-day COVID-19 mortality, the 206 primary outcome of this study. We also examined secondary outcomes that track clinical 207 indicators (e.g., hospitalization, hospital length-of-stay) and biomarkers (e.g., plasma IL-208 6 and nasopharyngeal SARS-CoV-2 levels) of progressive . (cohort features in Figure E1A , Table 2 , and Table E1 ). Hospitalized and nonhospitalized 216 patients were included, and a subset was studied through to the convalescence phase of 217 the infection. The distribution patterns of IR metrics and their associations with outcomes 218 in non-COVID-19 cohorts provided the framework for understanding the contributions of 219 pre-COVID-19 IR status to COVID-19 outcomes. We evaluated previously well-220 characterized non-COVID-19 cohorts of persons exposed to four types of antigenic 221 stimulation: (i) varied causes across lifespan (four cohorts; total n=8,201), including the 222 community-based SardiNIA aging cohort (n=3,896; 20 ) Clinical and laboratory assessments (e.g., scores of a clinical ordinal scale 32 , CD4+ and 239 CD8+ T-cell counts, and plasma IL-6 levels) were recorded (Supplementary methods). 240

These assessments were evaluated at baseline (presentation to the hospital or home 241 visit) as well as prospectively (daily) during hospitalization and at least once in the 242 convalescence phase. Cytomegalovirus (CMV) serostatus was evaluated at baseline. 243 RNA from nasal cells collected from hospitalized patients was sequenced (RNA-Seq) to 244 quantify SARS-CoV-2 levels as well as identify human genes whose expression levels 245

were associated with SARS-CoV-2 levels and survival (Supplementary methods). RNA 246 from peripheral blood cells was also sequenced. 247 248

Progressive COVID-19 was defined as progression along the continuum from 250 hospitalization to need for any respiratory support and/or death. The primary outcome 251 was all-cause 30-day COVID-19 mortality. Secondary outcomes included: hospitalization, 252 requirement of any respiratory support or mechanical ventilation; progression quantified 253 by an increase in an 8-category clinical ordinal scale (supplementary methods); hospital 254 length-of-stay (recovery rate); all-cause 120-day mortality; plasma IL-6 levels (biomarker 255 of inflammation and mortality 33-37 ); and nasal SARS-CoV-2 clearance, defined as time to 256 J o u r n a l P r e -p r o o f achievement of <10 counts of the viral nucleoprotein (N) gene. Clinical indicators of 257 nonprogressive vs. progressive COVID-19 disease course were nonhospitalized vs. 258 hospitalized patients, as well as survivors vs. nonsurvivors within 120 days of 259 presentation. Prespecified outcomes in the non-COVID-19 cohorts were all-cause age-260 adjusted mortality over 9 years in the FHS, severity of influenza infection, and hazard of 261 AIDS. A lower hazard of mortality in the COVID-19 cohort or FHS was defined as a 262 survival advantage. 263 264

To capture the cellular and molecular events that may associate with IR status, we derived 266 laboratory and transcriptomic metrics of IR, which served as predictors in this study. 267

Laboratory metrics of IR, termed immune health grades (IHGs), were derived on the 268 principles that: (i) IR tracks superior immunocompetence, (ii) peripheral blood CD8+ and 269

CD4+ T-cell levels influence immunity, and (iii) CD4+ lymphopenia is a characteristic of 270 aging, SLE, and HIV infection 38-51 . We posited that the level of equilibrium vs. 271 disequilibrium between peripheral blood CD8+ and CD4+ T-cells, rather than their 272 absolute values, may be more precise metrics of immunocompetence. Four IHGs (I to IV) 273 tracking the equilibrium between CD8+ and CD4+ T-cell counts were computed ( Figure  274 1A; Figure E1C ). Laboratory cutoffs were the lower interquartile bounds of the median 275 CD4+ count in otherwise healthy HIV-seronegative persons (800 cells/mm 3 ) 26, 27 and an 276 inverted CD4:CD8 T-cell ratio (<1.0) ( Figure 1A) . The CD4+ cutoff was used as ≥800 277

CD4-cells/mm 3 associated with near-normalized immune status in HIV+ persons 27 . An 278 inverted ratio was used as a cutoff as it is a mathematical reflection of expanded CD8+ 279 J o u r n a l P r e -p r o o f levels uncompensated by a concomitant increase in CD4+ T-cell levels. Thus, an inverted 280 ratio marks CD8-CD4 disequilibrium, signifying higher CD8+ levels with relatively higher 281 (IHG-III) or lower (IHG-IV) CD4+ counts ( Figure 1A, B) . To metricize CD4+ levels during 282 SARS-CoV-2 vs. HIV infections, we derived subgrades (suffixes a, b, and c) of IHG-II and 283 IHG-IV using CD4+ cutoffs demarcating AIDS (≤200 cells/mm 3 ) 52 and the median CD4+ Correspondingly, the GO-BP terms were defined as beneficial and detrimental traits. 296

Gene scores were computed by averaging the z-score normalized expression of all genes 297 comprising the GO-BP term. Gene scores of the traits (GO-BP terms) that associated 298 with 30-day mortality hazards during COVID-19 were examined for their associations with 299 mortality in the FHS. Traits that associated with mortality in the COVID-19 cohort and 300 FHS were examined for their associations with influenza symptom severity. curves were derived to illustrate cumulative events. Cox proportional hazards models 308 were used to calculate hazard ratios (HRs) for mortality in the COVID-19 cohort and FHS, 309 and rate ratios (RRs) for recovery rates (hospital length-of-stay) as well as nasal SARS-310

CoV-2 clearance in the COVID-19 cohort. Multivariable logistic and linear regression 311 models were used to compare secondary outcomes. RNA-sequencing analysis was 312 performed using DESeq 55 . All P values are 2-sided and shown without adjustment for 313 multiple testing unless specified. All analyses were performed using R, v3.5.0. 314

Based on median CD8+ and CD4+ counts, the IHGs tracked distinct CD8-CD4 318 equilibrium/disequilibrium profiles: IHG-I tracked lower CD8-higher CD4, IHG-II tracked 319 lowest CD8-lower CD4, IHG-III tracked highest CD8-higher CD4, and IHG-IV tracked 320 higher CD8-lowest CD4 (Figure E1D) . In a general population cohort (SardiNIA), across 321 all age ranges, IHG-I was the most common grade and IHG-I was uniformly 322 underrepresented in males ( Figure 1C,D) . The overall prevalence of IHG-I in the 323

SardiNIA cohort was 73%. IHG-I frequency declined progressively with age (85% and 324 46% in 18-24 and ≥80 years age strata, respectively). Reciprocally, the prevalence of the 325 other IHGs, especially IHG-II and IHG-IV, increased substantially with age ( Figure 1C ; 326 left). The IHG distribution patterns in younger women with SLE mirrored those of older 327 persons (≥80 years) in the SardiNIA cohort. In therapy-naïve HIV-seropositive adults, 328 higher plasma HIV viral loads induced IHG-IV (Figure 1C , right). The hierarchy of the 329 hazard of developing AIDS according to the IHG at presentation was: IHG-IV > IHG-III ~ 330 IHG-II > IHG-I, despite IHG-I and IHG-III marking higher CD4+ counts and IHG-II and 331 IHG-IV marking lower CD4+ counts ( Figure 1E ; Figure E1E ). Initiation of antiretroviral 332 therapy associated with reconstitution of IHG-I ( Figure 1C , far-right). The COVID-19 cohort comprised 522 patients, mostly males (n=468, 90%) with a median 350 age of 62 (IQR, 47-72) years; 349 (67%) were hospitalized and 173 (33%) were 351 nonhospitalized (Table 2, Figure E1A , Table E1A ). A total of 224 (43%) patients required 352 respiratory support, including 59 (11%) needing mechanical ventilation ( Figure E1A , 353 Table E1B ). Forty-eight (9%) and 69 (13%) patients died within 30 and 120 days of 354 presentation, respectively. The median (IQR) time to death within 30 and 120 days of 355 presentation was 13 (6-17) and 17 (11-36) days, respectively (Table E1B) . 356

Cohort characteristics by baseline IHG status are described ( Table 2) . Overall, 21%, 358 64%, 2%, and 13% individuals presented with IHG-I, IHG-II, IHG-III, and IHG-IV, 359 respectively (n=111, 335, 9, and 67, respectively; Figure 1C , middle). The median times 360 from symptom onset to presentation (baseline) was 6 (IQR, 2-9) days and did not differ 361 significantly by baseline IHG (P=0.26). Individuals presenting with IHG-I tended to be 362 younger with fewer comorbidities. Individuals presenting with IHG-IV vs. IHG-I were older 363

[median age (IQR), 69 (61-78) vs. 51 (42-65) years, respectively; P<0.001] and a greater 364 proportion had comorbidities, including chronic kidney disease and dementia ( 

Akin to the SardiNIA cohort, IHG-I was overrepresented in females vs. males in the 371 COVID-19 cohort (35% vs. 20%; P=0.01; Figure 1C ). Conversely, a lower proportion of 372 females vs. males presented with IHG-II (48% vs. 66%; P=0.01; Figure 1C ). As in the 373 SardiNIA cohort (Figure 1C , left), IHG-I frequency declined and IHG-II and IHG-IV 374 frequencies increased with age in the COVID-19 cohort ( Figure 1F , upper-left stacked 375 bars). However, at both the overall cohort level as well as within comparable age ranges, 376 IHG-I was underrepresented, whereas IHG-II and IHG-IV were overrepresented in the 377 COVID-19 vs. SardiNIA cohort ( Figure 1C ; Figure 1E ; Figure 1F , upper-left stacked 378 bars). Overall cohort-level differences in proportions were 21% vs. 73% for IHG-I, 64% 379 vs. 22% for IHG-II, and 13% vs. 3% for IHG-IV (P<0.001 for COVID-19 vs. SardiNIA inter-380 cohort differences). Additionally, while hospitalization rates increased with age, within 381 each age stratum, hospitalized patients were more likely to have IHG-II and IHG-IV at 382 presentation ( Figure 2A) . Conversely, nonhospitalized patients were more likely to have 383 IHG-I (Figure 2A) . IHG distributions were similar in younger and older patients who 384 required respiratory support and/or died ( Figure 1C ; Figure E1F ). 385

The underrepresentation of IHG-I vs. overrepresentation of IHG-II and IHG-IV was 387 attributable to SARS-CoV-2 infection as, during convalescence, younger and older 388 COVID-19 survivors reconstituted IHG frequencies to levels found in their corresponding 389 age groups in non-COVID-19 cohorts (SardiNIA cohort and healthcare workers; Figure  390 2B vs. 1C; Figure E2A ). The IHG reconstitution patterns assigned patients to the IR-391 dependent COVID-19 phenotypes ( Table 1) . Phenotype 1 corresponded to preservation 392 of superior IR (IHG-I) before and during early COVID-19. Phenotype 2 corresponded to 393 diathesis to degrade IHG-I during . Phenotype 3 corresponded to presentation 395 with and maintenance of IHG-II or IHG-IV during convalescence, suggesting that these 396 grades may have antedated COVID-19. 397

The 30-day mortality was lowest among patients with IHG-I compared to IHG-IV and IHG-399 II (1%, 16%, and 11%, respectively, P<0.001; Table E1B; Figure E2B ). Each one 400 increase in age independently associated with mortality (IHG-adjusted HR, 1.05; 95% CI, 401

1.03-1.08), as well as likelihood of hospitalization (IHG-adjusted OR, 1.06; 95% CI, 1.01-402 1.07), and need for respiratory support (IHG-adjusted OR, 1.04; 95% CI, 1.02-1.05). An 403 independent association of sex with these outcomes was not observed (data not shown). 404

After adjusting for age and sex, presentation with IHG-I vs. other grades was associated 405 with a lower HR for 30-day mortality (aHR, 0.12; 95% CI, 0.02-0.87) and 120-day mortality 406 (aHR, 0.17, 95% CI, 0.04-0.69) as well as a lower odds ratio (OR) for hospitalization 407 (aOR, 0.16; 95% CI, 0.10-0.26) and mechanical ventilation (aOR, 0.06; 95% CI, 0.01-408 0.45), and a more rapid recovery rate (aRR, 2.08; 95% CI, 1.40-3.07) ( Figure E2B) . 409 410 Compared with presentation with IHG-I, the age-adjusted HR for 30-day mortality in 411 patients presenting with IHG-II or IHG-IV was 8.05 (95% CI, 1.10-59.09) and 9.08 (95% 412 reasons, and because IHG-IV is the hallmark CD8-CD4 profile of therapy-naïve HIV-418 seropositive persons (Figure 1B,C) , we examined the differences in the origins and 419 associations of IHG-II and IHG-IV subgrades ( Figure 1B) . (6%) and IHG-IVb (4%) (Figure 2D; Figure E2C ). This finding suggests that these 427 subgrades were induced during COVID-19. Additionally, there was high correspondence 428 between the IR level (IHG status) reconstituted during convalescence and IR level during 429 acute COVID-19 ( Figure 2D ). Nearly all (92%) patients who presented with IHG-I 430 preserved IHG-I during convalescence. The proportion reconstituting IHG-I was 431

progressively lower in individuals presenting with IHG-IIa, IHG-IIb, and IHG-IIc (57%, 432 44%, and 20%, respectively). Meanwhile, 46% of the patients who presented with IHG-433 IV persisted with IHG-IV during convalescence ( Figure 2D ). These paired baseline-434 convalescence IHG distribution patterns indirectly indicate the possibility that pre-COVID-435 19 IHG status impacts IHG status at presentation during acute COVID-19. 436

The age-adjusted OR for hospitalization associated with IHG-II subgrades and IHG-IVb/c 438 vs. IHG-I at baseline were comparable to or greater than the IHG-adjusted OR of 439 probability of presenting with IHG-I declined with age ( Figure E2E) , the modeled 441 probability of hospitalization for a 30-year-old patient presenting with IHG-IIc (80%; 95% 442 CI, 48%-95%) was similar to that modeled for a 95-year-old patient with IHG-I (81%; 95% 443 CI, 67%-90%; Figure 2E ). Presentation with IHG-IV showed a similar increased 444 probability of hospitalization but lower than that associated with IHG-IIc ( Figure 2E) . The 445

age-independent prognostication of hospitalization by baseline IHG status was 446 attributable to our finding that, unlike aggregated lymphocyte values by age, lymphocyte 447 values by IHG status are range-bound across age ( Figure 1F ). Hence, IHGs provide a 448 uniform metric of IR across age. the clinical ordinal scale, (iii) need for any respiratory support, and (iv) dying within 30 or 464 120 days of presentation, was lowest to highest in patients presenting with IHG-IVa 465 followed by IHG-IVb, IHG-IIb, IHG-IVc, and IHG-IIc ( Figure E3C , E4A-C; Table E1B ,G). 466

The strength of the associations between baseline IHG status and these outcomes were 467 comparable to or greater than those of older age and were independent of age and body 468 mass index (Supplementary notes 1 and 2, Table E1F, G) . Seropositivity for CMV has been associated with the immunosenescence of age as well 478 as changes in CD4+ and CD8+ lymphocyte levels (e.g., the immune risk phenotype that 479 tracks an inverted ratio and CMV seropositivity) 56-60 . Because of these associations, we 480 examined whether the associations of IHGs with outcomes were attributable to CMV 481 seropositivity. Predictably, CMV seropositivity rates increased with age in the COVID-19 482 cohort; however, CMV serostatus did not independently associate with the outcomes of 483 mortality, hospitalization, or respiratory support (Supplementary note 5) . In contrast, 484 baseline IHGs associated with these outcomes independent of CMV serostatus 485 J o u r n a l P r e -p r o o f (Supplementary note 5) . This independent association may relate to our finding that 486 CMV seropositivity was differentially distributed between IHG-II vs. IHG-IV 487

were CMV-seronegative, whereas a greater proportion of persons presenting with IHG-489 IV (74%) were CMV-seropositive, and nearly 50% with IHG-I were CMV-seropositive 490 ( delayed clearance, respectively, of nasal SARS-CoV-2 levels ( Figure 3D ; Figure E7A ; 495 Table E4 ). Compared with baseline IHG-I, SARS-CoV-2 clearance rates were 496 significantly slower by 87% (RR, 0.13; 95% CI, 0.02-0.82) with IHG-IV and trended to be 497 slower by 72% (RR, 0.28; 95% CI, 0.05-1.44) with IHG-II ( Figure E7B) . Correspondingly, 498 SARS-CoV-2 levels were higher in nonsurvivors and patients requiring mechanical 499 ventilation ( Figure E7C) . Genes in the nasal transcriptome whose expression levels 500 associated with both lower SARS-CoV-2 levels and increased survival related to 501 preservation of epithelial integrity as well as robust antiviral and Th2 responses and 502 controlled inflammatory responses (Figure E8 ; Tables E5A-C, E6A; Supplementary 503 note 6). Genes associated with higher SARS-CoV-2 levels also correlated with higher 504 levels of ACE2, the SARS-CoV-2 receptor 61 ; these genes related to virus-induced 505 inflammation ( Figure E8B; Table E5D ). identified 42 detrimental and 9 beneficial traits (GO-BP terms) and 28 beneficial genes 510 ( Figure E8A, Tables E6B, E7) . These traits/genes segregated into four categories, 511 depending on whether higher levels of detrimental traits and lower levels of the beneficial 512 traits/genes associated with increased mortality hazards in either, both, or neither the 513 COVID-19 cohort and FHS (Figure 4A; Figure E9 ; Table E8A-B). Category 1 comprised 514 17 detrimental and 6 beneficial traits, along with 28 beneficial genes whose levels defined 515 a unique IC low -IF high state associated with increased mortality hazards only in the COVID-516 19 cohort (Table E8A, B) . The unique IC low state related to lower levels of the beneficial 517 traits/genes linked to MHC class II-dependent antigen processing/presentation, the 518 tyrosine signaling pathway, and HLA genes involved in T-cell costimulation (e.g., GO-BP 519 terms 28, 29, and 33, respectively; Figure 4A ). The unique IF high state related to higher 520 levels of the detrimental traits linked to the inflammatory response to virus (e.g., GO-BP 521 terms 1, 5, and 15 corresponding to type I interferon (IFN) signaling pathway, response 522 to virus, and IFN-mediating signaling pathway, respectively; Figure 4A ). 523 524 Category 2 comprised 12 detrimental and 3 beneficial traits whose levels defined a shared 525 IC low -IF high state associated with mortality hazards in both the COVID-19 cohort and FHS 526 (Table E8C ). The shared IC low state related to lower levels of shared beneficial traits 527 linked to T-cell costimulation, T-cell signaling, and immune responses with genes (e.g., 528

CCR5, CCR7, IL7R) essential for the integrity of T-cell homeostasis (e.g., GO-BP terms 529 30, 31, and 32). The shared IF high state related to higher levels of shared detrimental 530 traits related to inflammatory responses commonly elicited during antigenic challenges 531 J o u r n a l P r e -p r o o f experienced during aging (e.g., GO-BP terms 4 and 13 corresponding to defense 532 response to gram-positive bacteria and response to lipopolysaccharide, respectively; 533 Figure 4A ; Figure E10 ; Table E8C ). Category 3 comprised 8 detrimental traits 534 associated with an increased mortality hazard that achieved statistical significance only 535 in the FHS (e.g., GO-BP terms 24, 25; Figure 4A ; Figure E8A ). Category 4 comprised 5 536 detrimental traits that did not achieve statistical significance for mortality hazards in either 537 the COVID-19 cohort or FHS (Figure E9) . 538

The unique and shared IC low -IF high states associated with nonsurvivors, patients requiring 540 mechanical ventilation, older individuals, and those presenting with IHG-II or IHG-IV 541 ( Figure 4B, Figure E11 , Table E9A ). Similar associations were observed with trait levels 542 measured during the disease course ( Figure E12; Table E9B , C). Additionally, baseline 543 levels of 48 of the 51 traits and the 28 beneficial genes associated with baseline IHG 544 status after controlling for age (Table E9D) . 545 546 Our discovery of a shared IC high -IF low state that associated with a survival advantage in 547 both the COVID-19 cohort and FHS was congruent with four additional salutary 548 associations in non-COVID-19 cohorts. First, akin to our findings in the COVID-19 cohort 549 ( Figure 4B, Figure E11 ), in non-COVID-19 cohorts (Figure E13) , the shared IC high -IF low 550 state that associated with COVID-19 survival marked individuals with IHG-I, whereas the 551 shared IC low -IF high state that associated with COVID-19 mortality marked persons with 552 IHG-IIc and IHG-IVc. Second, the shared IC high -IF low state was overrepresented in 553 females vs. males across age in the FHS (Figure E14A) . In both sexes, levels of the 554 J o u r n a l P r e -p r o o f shared IC high -IF low state declined proportionately during aging; however, comparable 555 levels of this state associated with a greater survival benefit in females (Figure E14B ; 556 Table E8D ). Third, beneficial traits that defined the shared IC high state co-clustered at high 557 correlation levels with a gene signature [immune age (IMM-AGE)] associated with lower 558 hazards of cardiovascular disease and mortality in the FHS 40 ( Figure E15) . 559

Correspondingly, higher expression levels of the IMM-AGE signature associated with a 560 lower mortality hazard in the COVID-19 cohort (HR, 0.91; 95% CI, 0.84-0.98). Notably, 561 higher levels of the IMM-AGE score associated with a lower abundance of immune 562 markers signifying immunosenescence in the FHS 40 . Fourth, the shared IC high -IF low state 563 was associated with less-severe influenza infection, including after nasal inoculation of 564 influenza virus in otherwise healthy younger adults ( Figure E16) . 565 566

Through evaluations of COVID-19 and non-COVID-19 cohorts, we uncovered the 568 conserved features of a suspected but previously uncharacterized sexually dimorphic, 569 antigen-activated, immunologic program that associates independently with lower 570 immunocompetence and increased inflammation at any age. We propose that relative 571 resistance to activation of this immunologic program is more common in females and 572 signifies IR. Laboratory (CD8-CD4 equilibrium/disequilibrium-based) and transcriptomic 573 (gene expression signatures) metrics signifying preservation of IR were associated with 574 salutary outcomes: a survival advantage in persons either with or without COVID-19, as 575 well as resistance to development of a progressive disease course during infections with 576 SARS-CoV-2, influenza viruses, or HIV. We report on three observations relevant to 577 J o u r n a l P r e -p r o o f understanding the basis for the age-independent and sex-biased differences in 578 susceptibility to developing severe COVID-19, as well as improving clinical care and 579 identifying therapeutic targets for mitigation of progressive COVID-19. 580 581 First, we derived readily measurable metrics of IR that predicted all-cause, 30-day 582 COVID-19 mortality independent of age, sex, body mass index, and CMV serostatus. 583

Correspondingly, use of these metrics predicted secondary outcomes that included 584 clinical indicators (e.g., hospitalization, mechanical ventilation) and biomarkers (e.g., 585

plasma IL-6 and nasopharyngeal SARS-CoV-2 levels) indicative of progressive COVID-586

19. Second, we distinguished and quantified the individual contributions to COVID-19 587 outcomes of age vs. age-independent deficits in IR that antedated SARS-CoV-2 infection 588 vs. age-independent deficits in IR that are uniquely induced in response to infection. 589

These findings provide support for three novel, IR-dependent COVID-19 phenotypes 590 linked to differential survival risks (Table 1) , predicated on whether persons had the 591 proclivity to preserve IR before and during COVID-19, at any age. Across age strata, 592 persons preserving metrics indicative of superior IR before and during early COVID-19 593 were more likely to manifest a survival advantage and nonprogressive COVID-19 594 (phenotype 1; Table 1 ). Females were more likely to manifest phenotype 1. The 595 distinction between the negative effects of age vs. pre-infection or infection-induced 596 deficits in IR at any age has clinical implications for the prediction and prevention of 597 progressive COVID-19, as well as for the personalization of care (Supplementary note 598 7; Figure E17, E18) . Third, we identified two sets of IR-associated traits linked to 599 immunocompetence or inflammation that associated with survival: one set comprised 600 J o u r n a l P r e -p r o o f traits that uniquely associated with survival during COVID-19, whereas the other set 601 comprised shared traits that associated with mortality in persons with or without COVID-602

whereas the latter set of traits points to therapeutic targets for extending longevity. The inter-cohort differences in IHG distributions underscore that age is an imperfect proxy 620 for antigenic experience. In response to antigenic experience, the prevalence of IHG-I 621 declines with age, increasing the pool of at-risk persons with IHG-II and IHG-IV. Thus, at 622 any age, the presence of IHG-II or IHG-IV vs. IHG-I before COVID-19 likely heightens the 623 J o u r n a l P r e -p r o o f risk of developing progressive COVID-19. This is a parsimonious basis for our finding 624 that, while hospitalization rates increased with age, irrespective of age, patients who were 625 hospitalized, required respiratory support, and/or died were more likely to present with 626 IHG-II or IHG-IV vs. IHG-I. Moreover, presentation with IHG-II or IHG-IV vs. IHG-I 627 associated with delayed nasal SARS-CoV-2 clearance, a feature associated with 628 mortality in our cohort. In a general HIV-seronegative community population, nearly 12% with IHG-I, presentation with IHG-IIc or IHG-IVc was associated with a ~19-or ~12-fold 653 higher hazard of death in 30 days, respectively, and recovery times that were 67% and 654 88% longer, respectively. Persons presenting with IHG-IVc vs. IHG-IIc tended to be older, 655 have more comorbidities, were CMV seropositive, and displayed contrasting IHG 656 reconstitution patterns during convalescence. While CMV seropositivity increased with 657 age, CMV serostatus was not associated with mortality. Thus, the IHG at presentation 658 was not stochastic, but likely reflected the antigenic experience of the host before COVID-659 19 and response to SARS-CoV-2 infection. 660

Four findings highlight the substantial impact of baseline IHG status on COVID-19 662 outcomes: (i) compared to presentation with IHG-I, presentation with IHG-IIc increased 663 the absolute risk of 30-day mortality by 28 additional deaths per 100 persons, (ii) 664 compared to presentation with IHG-IIa, presentation with IHG-IIc associated with an 665 excess of 26 additional deaths per 100 persons, (iii) while more older persons presented 666 with IHG-IIc or IHG-IVc, the age-adjusted associations of these grades with COVID-19 667 outcomes were at least as strong as those associated with older age, and (iv) the 668 J o u r n a l P r e -p r o o f associations of IHG status with COVID-19 mortality were independent of both age and 669 CMV serostatus, as well as body mass index, a risk factor for severe 63 . 670 671 Transcriptomic data support that a switch from IHG-I to IHG-II or IHG-IV before or during 672 COVID-19 may associate with an immunosuppressive, pro-inflammatory state that 673 contributes to mortality. We identified two distinct IC low -IF high states that associated with 674 COVID-19 mortality. The shared IC low -IF high state likely antedated COVID-19, as it 675 associated with mortality not only in persons with COVID-19 but also participants in the 676 Thus, irrespective of COVID-19 status, superior IR was indicated by IHG-I linked to a 687 shared IC high -IF low state, whereas deficits in IR were indicated by IHG-II or IHG-IV linked to 688 shared IC low -IF high states. Females were more successful in preserving indicators of 689 superior IR than males, as well as in manifesting a longevity advantage compared with 690 males in the FHS, even after correction for differences in the levels of IR between the 691 sexes. Congruently, during COVID-19, more females presented with IHG-I, potentially 692 explaining why the risk of developing progressive COVID-19 is lower in females. 693

As the baseline IHGs independently predict COVID-19-associated mortality and recovery, 695 balancing IHG status across trial intervention vs. placebo arms may reduce confounding 696 in clinical studies (Supplementary note 7; Figure E18) . Moreover, assessment of IHGs 697 may allow for individualized care and tailoring therapies. During COVID-19, levels of the 698 unique and shared IC low -IF high states were highest in persons presenting with IHG-IIc or 699 IHG-IVc and corresponded to an immunodeficient-hyperinflammatory state characterized 700 by uncontrolled inflammation, inadequate MHC class II responses, deficits in T-cell co-701 stimulation/signaling, higher plasma IL-6 levels, and higher nasal SARS-CoV-2 levels 702 (Supplementary note 7; Figure E18 ). Gene expression analysis suggests that the failure 703 to mount effective antiviral and immune responses in the nasal compartment may underlie 704 both higher SARS-CoV-2 burden and increased mortality, as well as correlate with higher 705 expression of ACE2, the receptor for SARS-CoV-2 61 (Supplementary note 6) . Thus, 706 presentation with or rapid advancement to IHG-IIc or IHG-IVc serves as an early indicator 707 of progressive disease, even before worsening respiratory function. Early targeting of the 708 IC low -IF high state in persons presenting with or advancing to IHG-IIc and IHG-IVc may 709 mitigate disease progression. This can potentially be achieved via combinatorial therapies 710 with immunomodulators (e.g., Baricitinib) and anti-inflammatory agents (e.g., interleukin-711 6 signaling inhibitors). failure to improve IR metrics). We found that all patients in our cohort with presumed 730 persistent COVID-19 had persistent IHG-IIc or IHG-IVc, suggesting that a failure to clear 731 SARS-CoV-2 burden, possibly due to deficits in IR, may contribute to this persistence. In 732 such patients, IHGs were used to help identify those more likely to have persistent 733 COVID-19, warranting aggressive/alternative therapeutic approaches including 734 prolongation or reinitiation of remdesivir, corticosteroids, and/or initiation of 735 immunomodulators (e.g., Baricitinib). 736

At the time of this paper, the US Food and Drug Administration is strategizing COVID-19 738 vaccine booster doses for those who are "immunocompromised" and face a greater risk 739 from infection or re-infection 64 . Yet, identifying persons who are "immunocompromised" 740 beyond qualifying comorbidities (e.g., history of cancer, transplant recipients, receiving 741 immunosuppressant medications), or those with advanced age, remains obscure and 742 limited. IHGs track immunocompetence and inflammation status independent of age. For 743 example, up to 14% of a general population manifested IHG-IV, a grade that is highly 744 prevalent in therapy-naïve HIV+ persons. Hence, assessment of IHG status may provide 745 a means to accurately and precisely gauge "immunocompromised" status relevant for 746 prioritization of booster doses and other preventative therapies, regardless of age. 747

There are limitations of our study. The COVID-19 cohort comprised mostly male veterans, 749 many of whom were older and had comorbidities; these features may not be 750 generalizable. Second, therapies for COVID-19 could confound associations. Treatment 751 decisions in our cohort were not dictated by participation in any concomitant clinical trials, 752 and baseline IHG status was used for defining associations. Third, we were unable to 753 obtain viral cultures. Fourth, defining the association of IHG status with post-acute 754 sequelae of SARS-CoV-2 infection was beyond the scope of this study. 755 756 In summary, we identified age-independent, female-biased processes linked to higher 757 immunocompetence and lower inflammation signifying IR that bridge longevity, COVID-758 J o u r n a l P r e -p r o o f 19 survival, and resistance to AIDS and severe influenza. Thus, the IR metrics have value 759 for precision immune health monitoring across lifespan, irrespective of COVID-19 status. 760

Our data favor a mechanistic model wherein gain of detrimental function (inflammation) 761 and loss of beneficial functions (lower immunocompetence) signifying IR deficits 762 independently and synergistically contribute to mortality in persons with or without 763 COVID-19 (Supplementary note 7) . Across all age ranges, the relative burden of 764 progressive COVID-19 is dependent on the prevalence of individuals with a proclivity to 765 preserve vs. degrade IR before and during COVID-19, with males having a diathesis to 766 degrade IR. The magnitude of the absolute risk differences for 30-day mortality 767 associated with IHG status at presentation underscores the need for a combinatorial 768 approach with immunomodulators and anti-inflammatory agents to mitigate progression 769 of pre-existing IR deficits and/or promote the rapid restoration of the IR status that 770 antedated SARS-CoV-2 infection. 771 

paper is dedicated to the patients with COVID-19 who died at our institution and Dr

Additional 775 members of the South Texas Veterans Health Care System COVID-19 team (Affiliated 776 to South Texas Veterans Health Care System

Renee 790 L. Reichelderfer, Evan M Renz

Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in 799 the US

Risk 801 Factors Associated With Mortality Among Patients With COVID-19 in Intensive 802 Care Units in

Clinical Outcomes in Young US Adults Hospitalized With COVID-19. 805

COVID-19) -United States

Sex 810 differences in immune responses that underlie COVID-19 disease outcomes. 811 Nature

Sex differences in immune responses

Immune determinants of COVID-19 disease presentation and severity

Considering how 817 biological sex impacts immune responses and COVID-19 outcomes

Male sex identified by global COVID-19 meta-analysis as a risk factor for 821 death and ITU admission

Fish EN. The X-files in immunity: sex-based differences predispose immune 825 responses

Nhamoyebonde S, Leslie A. Biological differences between the sexes and 829 susceptibility to tuberculosis

Sex, immunity and influenza

Sex Differences in Lifespan

Women live longer than men even during severe famines and 836 epidemics

Gender, 838 aging and longevity in humans: an update of an intriguing/neglected scenario 839 paving the way to a gender-specific medicine

Persistence 841 and Evolution of SARS-CoV-2 in an Immunocompromised Host

844 Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

The Framingham Heart Study and 849 the epidemiology of cardiovascular disease: a historical perspective

Temporal 852 dynamics of host molecular responses differentiate symptomatic and 853 asymptomatic influenza a infection

Neutrophils-related 855 host factors associated with severe disease and fatality in patients with influenza 856 infection

Progression of whole-blood transcriptional signatures from interferon-induced to 859 neutrophil-associated patterns in severe influenza

Modular transcriptional repertoire analyses of adults with systemic lupus 862 erythematosus reveal distinct type I and type II interferon signatures

T-cell recovery with earlier HIV-1 antiretroviral therapy. The New England journal 866 of medicine

Influence 868 of the timing of antiretroviral therapy on the potential for normalization of immune 869 status in human immunodeficiency virus 1-infected individuals

872 Clinical outcomes of elite controllers, viremic controllers, and long-term 873 nonprogressors in the US Department of Defense HIV natural history study

876 Outcomes of highly active antiretroviral therapy in the context of universal access 877 to healthcare: the U.S. Military HIV Natural History Study

Cumulative viral load and virologic decay patterns after antiretroviral 881 therapy in HIV-infected subjects influence CD4 recovery and AIDS

Clinical and immunological 930 features of severe and moderate coronavirus disease 2019

Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia

Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with 937 COVID-19 ARDS

CD4 percentage, CD4 number, and 939 CD4:CD8 ratio in HIV infection: which to choose and how to use

Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of 943 lymphopenia with clinical manifestations, serologic abnormalities, disease activity, 944 and damage accrual

Revised classification system for HIV infection and expanded 949 surveillance case definition for AIDS among adolescents and adults

952 Preservation of epithelial cell barrier function and muted inflammation in resistance 953 to allergic rhinoconjunctivitis from house dust mite challenge

Repetitive aeroallergen challenges elucidate maladaptive epithelial and 957 inflammatory traits that underpin allergic airway diseases

Differential expression analysis for sequence count data

Disease 962 drivers of aging

The silent war of CMV in aging and HIV infection

Mechanisms Underlying T Cell Immunosenescence: Aging and 966 Cytomegalovirus Infection

Inflammageing: chronic inflammation in ageing, 968 cardiovascular disease, and frailty

Immunosenenescence: role of cytomegalovirus

Angiotensin-converting 972 enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and 973 potential therapeutic target

cohort by sex, hospitalization and survivor status, and nonsurvivors by age. Right: IHG in 992 therapy-naïve HIV+ participants (with known dates of seroconversion) at entry into the 993 Natural History Study by entry viral load (VL; <1K, 1-10K, 10-100K, ≥100K copies/mL; K, 994 x10 3 ). Rightmost: IHGs before and after at least 5 years of antiretroviral therapy (ART representative genes (right) in each trait are shown. The association of these traits was 1044 analyzed in the FHS for 9-year survival. Forest plots are categorized and color-coded to 1045 represent shared and unique significant associations (FDR<0.1) in these two cohorts. 1046 Figure E9 and In COVID-19 patients, phenotype 1 is defined by a pre-COVID-19 IC high -IF low state and resistance to induction of a IC low -IF high state in response to SARS-CoV-2-associated antigenic stimulation; phenotype 2 is defined by a pre-COVID-19 IC high -IF low state and susceptibility to induction of a IC low -IF high state in response to SARS-CoV-2-associated antigenic stimulation, and phenotype 3 is defined by a pre-COVID-19 IC low -IF high state and susceptibility to induction of a IC low -IF high state in response to SARS-CoV-2-associated antigenic stimulation. Corollaries (longevity, influenza infection severity, and AIDS risk) associated with pre-COVID-19 IC-IF states are contrasted with corollaries of pre-COVID-19 plus SARS-CoV-2-induced IC-IF states. † Longevity evaluated in the non-COVID-19 HIV-seronegative, Offspring cohort of the Framingham Heart Study; survival advantage and disadvantage signify lower and higher hazards of mortality over 9 years, respectively. ‡ Evaluated in non-COVID-19 HIV-seronegative, influenza infection challenge and natural influenza infection cohorts. § Evaluated in a non-COVID-19 HIV infection natural history cohort. ¶ Evaluated in a COVID-19 cohort; survival advantage and disadvantage signify lower and higher hazards of mortality, respectively during COVID-19. Additive survival disadvantage refers to the combined effects of pre-COVID-19 IC low -IF high state and the unique infection-induced IC low -IF high state induced in COVID-19 patients. (2) 3 (3) 6 (2) 0 (0) 4 (6) 0.26 Myocardial infarction 4 (1) 0 (0) 3 (1) 1 (11) 0 (0) 0.09 Atrial fibrillation 37 (7) 7 (6) 24 (7) 0 (0) 6 (9) 0.91 Peripheral vascular disease 30 (6) 4 (4) 18 (5) 0 (0) 8 (12) 0.15 Cerebrovascular accident 33 (6) 5 (5) 18 (5) 1 (11) 9 (13) 0.06 Active, lymphoma 3 (1) 0 (0) 1 (0) 0 (0) 2 (3) 0.12 Active, leukemia 2 (0) 0 (0) 1 (0) 0 (0) 1 (1) 0.31 Active, solid tumor 11 (2) 1 (1) 5 (1) 0 (0) 5 (7) 0.03 History of cancer 34 (7) 7 (6) 14 (4) 2 (22) 11 (16) 0.001 J o u r n a l P r e -p r o o f HIV 9 (2) 1 (1) 7 (2) 0 (0) † Race or ethnicity and sex was as recorded in electronic medical record. ‡ Body mass index is the weight (kilograms) divided by the square of the height (meters). § End-stage renal disease was defined as requiring hemodialysis. ¶ Scores on the clinical ordinal scale are as follows: 1, not hospitalized, no limitations of activities; 2, not hospitalized, limitation of activities, home oxygen requirement, or both; 3, hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care; 4, hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (COVID-19-related or other medical conditions); 5, hospitalized, requiring any supplemental oxygen; 6, hospitalized, receiving noninvasive ventilation or use of high-flow oxygen devices; 7, hospitalized, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation; and 8, death.